var data={"title":"Treatment regimens for Helicobacter pylori","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment regimens for Helicobacter pylori</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/contributors\" class=\"contributor contributor_credentials\">Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/contributors\" class=\"contributor contributor_credentials\">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 02, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple antibiotic regimens have been evaluated for <em>Helicobacter pylori</em> therapy [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/1-5\" class=\"abstract_t\">1-5</a>]. However, few regimens have consistently achieved high eradication rates. There are also limited data on <em>H. pylori</em> antibiotic resistance rates to guide therapy. The treatment regimen that is selected must consider local antibiotic resistance patterns (if known), previous exposure and allergies to specific antibiotics, cost, side effects, and ease of administration.</p><p>This topic will review treatment regimens for <em>H. pylori</em>. The bacteriology, epidemiology, and diagnostic tests for <em>H. pylori</em> infection are discussed elsewhere. (See <a href=\"topic.htm?path=indications-and-diagnostic-tests-for-helicobacter-pylori-infection\" class=\"medical medical_review\">&quot;Indications and diagnostic tests for Helicobacter pylori infection&quot;</a> and <a href=\"topic.htm?path=bacteriology-and-epidemiology-of-helicobacter-pylori-infection\" class=\"medical medical_review\">&quot;Bacteriology and epidemiology of Helicobacter pylori infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4260690167\"><span class=\"h1\">INDICATIONS FOR TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients with evidence of active infection with <em>H. pylori </em>should be offered treatment. Indications for testing for <em>H. pylori</em> infection are discussed in detail separately. (See <a href=\"topic.htm?path=indications-and-diagnostic-tests-for-helicobacter-pylori-infection#H2\" class=\"medical medical_review\">&quot;Indications and diagnostic tests for Helicobacter pylori infection&quot;, section on 'Indications for testing'</a>.)</p><p class=\"headingAnchor\" id=\"H545843828\"><span class=\"h1\">INITIAL ANTIBIOTIC THERAPY</span></p><p class=\"headingAnchor\" id=\"H3817818346\"><span class=\"h2\">Approach to selecting an antibiotic regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The choice of initial antibiotic regimen to treat <em>H. pylori</em> should be guided by the presence of risk factors for macrolide resistance and the presence of a penicillin allergy [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/6\" class=\"abstract_t\">6</a>]. In patients with risk factors for macrolide resistance, clarithromycin-based therapy should be avoided. A suggested approach to the selection of antibiotics for initial treatment of <em>H. pylori</em> infection is outlined in the algorithm (<a href=\"image.htm?imageKey=GAST%2F112678\" class=\"graphic graphic_algorithm graphicRef112678 \">algorithm 1</a> and <a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>). (See <a href=\"#H3453806024\" class=\"local\">'Clarithromycin-based therapy'</a> below.)</p><p>Risk factors for macrolide resistance include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior exposure to macrolide therapy for any reason</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High local <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> resistance rates &ge;15 percent or eradication rates with clarithromycin triple therapy &le;85 percent</p><p/><p>In the United States, given the limited information on antimicrobial resistance rates, we generally assume <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> resistance rates are greater than 15 percent unless local data indicate otherwise [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H1285242199\"><span class=\"h3\">Patients with risk factors for macrolide resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with risk factors for macrolide resistance, we use bismuth quadruple therapy (<a href=\"image.htm?imageKey=GAST%2F112678\" class=\"graphic graphic_algorithm graphicRef112678 \">algorithm 1</a> and <a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/6,8-15\" class=\"abstract_t\">6,8-15</a>]. (See <a href=\"#H4045763521\" class=\"local\">'Bismuth quadruple therapy'</a> below and <a href=\"#H2609998802\" class=\"local\">'Levofloxacin based therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H2227870566\"><span class=\"h3\">Patients without risk factors for macrolide resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients without risk factors for macrolide resistance, we use clarithromycin-based triple therapy with a proton pump inhibitor (PPI), <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, and <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> (<a href=\"image.htm?imageKey=GAST%2F112678\" class=\"graphic graphic_algorithm graphicRef112678 \">algorithm 1</a> and <a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>). Other first-line antibiotic regimens for these patients include bismuth quadruple therapy and clarithromycin-based concomitant therapy. In penicillin-allergic individuals, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> can be substituted for amoxicillin. In patients with metronidazole exposure within the past few years, we use bismuth quadruple therapy. (See <a href=\"#H3453806024\" class=\"local\">'Clarithromycin-based therapy'</a> below and <a href=\"#H4045763521\" class=\"local\">'Bismuth quadruple therapy'</a> below and <a href=\"#H3788833783\" class=\"local\">'Concomitant therapy'</a> below.)</p><p>Other potential first-line treatment regimens include clarithromycin-based hybrid or sequential therapy [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/6\" class=\"abstract_t\">6</a>]. However, the clarithromycin-based hybrid therapy has not been universally endorsed as an option for first-line therapy given its complexity [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/8\" class=\"abstract_t\">8</a>]. In addition, some North American guidelines recommend against the use of sequential therapy as a first-line regimen given the lack of data from North American trials [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H740837509\"><span class=\"h2\">Duration of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We recommend clarithromycin-based triple therapy and bismuth quadruple treatment regimens for <em>H. pylori</em> be administered for 14 days. Our recommendations are largely consistent with current guidelines which recommend extended (10 to 14 days) treatment with all antibiotic regimens for <em>H. pylori </em>(<a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/8,9,11\" class=\"abstract_t\">8,9,11</a>]. </p><p class=\"headingAnchor\" id=\"H1588496158\"><span class=\"h2\">Tolerability and compliance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Side effects are reported in up to 50 percent of patients taking one of the triple therapy regimens [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/4,16\" class=\"abstract_t\">4,16</a>]. The adverse effects are usually mild; fewer than 10 percent of patients stop treatment due to side effects [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/16\" class=\"abstract_t\">16</a>]. Clarithromycin-based triple therapy and bismuth quadruple therapy appear to have similar efficacy, compliance, and tolerability [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/17\" class=\"abstract_t\">17</a>]. While the tolerability and compliance of sequential, hybrid, and concomitant therapies appears to be similar to triple therapy in clinical trials, these regimens are more complex. Side effects of individual drugs are discussed in detail separately. (See <a href=\"topic.htm?path=metronidazole-an-overview\" class=\"medical medical_review\">&quot;Metronidazole: An overview&quot;</a> and <a href=\"topic.htm?path=azithromycin-clarithromycin-and-telithromycin#H19\" class=\"medical medical_review\">&quot;Azithromycin, clarithromycin, and telithromycin&quot;, section on 'Adverse reactions'</a> and <a href=\"topic.htm?path=tetracyclines#H14\" class=\"medical medical_review\">&quot;Tetracyclines&quot;, section on 'Adverse reactions'</a> and <a href=\"topic.htm?path=fluoroquinolones#H24\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;, section on 'Adverse reactions'</a> and <a href=\"topic.htm?path=proton-pump-inhibitors-overview-of-use-and-adverse-effects-in-the-treatment-of-acid-related-disorders#H59974871\" class=\"medical medical_review\">&quot;Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders&quot;, section on 'Adverse effects'</a> and <a href=\"topic.htm?path=antiulcer-medications-mechanism-of-action-pharmacology-and-side-effects#H5\" class=\"medical medical_review\">&quot;Antiulcer medications: Mechanism of action, pharmacology, and side effects&quot;, section on 'Adverse effects'</a>.)</p><p class=\"headingAnchor\" id=\"H1032686964\"><span class=\"h2\">Antibiotic regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial antibiotic regimens for <em>H. pylori </em>can be broadly divided into bismuth, <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>, and <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> containing regimens (<a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a> and <a href=\"image.htm?imageKey=GAST%2F112678\" class=\"graphic graphic_algorithm graphicRef112678 \">algorithm 1</a>).</p><p class=\"headingAnchor\" id=\"H4045763521\"><span class=\"h3\">Bismuth quadruple therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bismuth quadruple therapy consists of <a href=\"topic.htm?path=bismuth-subsalicylate-drug-information\" class=\"drug drug_general\">bismuth subsalicylate</a>, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>, and a PPI given for 14 days [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/18\" class=\"abstract_t\">18</a>]. A combination capsule containing bismuth subcitrate, metronidazole, and tetracycline (Pylera) has been approved by the United States Food and Drug Administration. A regimen using the combination capsule (three capsules four times daily plus PPI twice daily) is somewhat simpler than standard quadruple therapy (four to eight pills four times daily and a PPI twice daily). For details, refer to <a href=\"topic.htm?path=bismuth-subcitrate-metronidazole-and-tetracycline-drug-information\" class=\"drug drug_general\">bismuth subcitrate-metronidazole-tetracycline</a> in Lexicomp. If tetracycline is not available, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> (100 mg twice daily) may be substituted [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/19,20\" class=\"abstract_t\">19,20</a>].</p><p>In North American trials, the mean eradication rate with bismuth quadruple therapy administered for 10 days was 91 percent [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/9,21,22\" class=\"abstract_t\">9,21,22</a>]. A 2013 meta-analysis of 12 randomized trials reported comparable eradication rates with bismuth quadruple therapy and <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> triple therapy (78 and 69 percent, respectively) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/23\" class=\"abstract_t\">23</a>]. However, there was significant heterogeneity in treatment duration, drug dosing, and the meta-analysis included trials performed in North America, Europe, and Asia. No significant differences in efficacy were noted when both regimens were administered for 10 to 14 days. <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">Metronidazole</a> resistance has a limited impact on eradication success rate in patients treated with bismuth quadruple therapy and can be overcome by increasing the dose, duration, or frequency of therapy [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/24\" class=\"abstract_t\">24</a>]. (See <a href=\"#H3167044966\" class=\"local\">'Factors associated with antibiotic treatment failure'</a> below.)</p><p class=\"headingAnchor\" id=\"H3453806024\"><span class=\"h3\">Clarithromycin-based therapy</span></p><p class=\"headingAnchor\" id=\"H3153939224\"><span class=\"h4\">Triple therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">Clarithromycin</a> triple therapy consists of clarithromycin, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, and a PPI, all given twice daily (<a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>). We suggest treatment for 14 days, as longer duration of treatment may be more effective in curing infection [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/6,8,25\" class=\"abstract_t\">6,8,25</a>]. <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">Metronidazole</a> can be substituted for amoxicillin in penicillin-allergic individuals. PPI-clarithromycin-metronidazole and PPI-clarithromycin-amoxicillin regimens are equivalent [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/11,26\" class=\"abstract_t\">11,26</a>]. </p><p>Eradication rates for <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> triple therapy in the United States are below 80 percent [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/6\" class=\"abstract_t\">6</a>]. The eradication rates of clarithromycin triple therapy is significantly impacted by the presence of clarithromycin resistance [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/17,23\" class=\"abstract_t\">17,23</a>]. In a meta-analysis of two trials in which patients were treated with clarithromycin triple therapy, eradication rates for clarithromycin-sensitive <em>H. pylori </em>strains and clarithromycin-resistant strains were 90 and 22 percent respectively [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/17\" class=\"abstract_t\">17</a>]. </p><p class=\"headingAnchor\" id=\"H3788833783\"><span class=\"h4\">Concomitant therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Concomitant therapy consists of a <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, a nitroimidazole (<a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">tinidazole</a> or <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>), and a PPI administered together (<a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>). If concomitant therapy is used to treat <em>H. pylori,</em> the regimen should be continued for 10 to 14 days.</p><p>While efficacy data from the North America are lacking, in a meta-analysis of 19 randomized trials that included 2070 individuals in Europe, Asia and Latin America, eradication rates were significantly higher with concomitant quadruple therapy as compared with <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> triple therapy (90 and 78 percent, respectively) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/27\" class=\"abstract_t\">27</a>]. The efficacy of concomitant therapy was decreased in patients with clarithromycin-resistant <em>H. pylori </em>infection but to a smaller degree as compared with clarithromycin triple therapy. In this meta-analysis, longer durations of therapy (7 to 10 versus 3 to 5) were associated with a trend toward higher cure rates. However, additional studies are needed to assess whether extending the duration of concomitant therapy to 14 days results in improved eradication rates. </p><p class=\"headingAnchor\" id=\"H1644077299\"><span class=\"h4\">Hybrid therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hybrid therapy consists of <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> and a PPI for seven days followed by amoxicillin, <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>, a nitroimidazole, and a PPI for seven days (<a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>). Hybrid therapy has been suggested as an alternative to clarithromycin triple therapy. However, the complexity of the treatment regimen has limited its use as a first-line regimen in the treatment of<em> H. pylori.</em></p><p>In a meta-analysis that included six randomized trials, which compared hybrid therapy with sequential <span class=\"nowrap\">and/or</span> concomitant therapy, the eradication rate with hybrid therapy was 89 percent [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/28\" class=\"abstract_t\">28</a>]. The efficacy and tolerability of hybrid therapy is comparable to concomitant and sequential regimens [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/29\" class=\"abstract_t\">29</a>]. Hybrid therapy has not been directly compared with clarithromycin-based triple therapy. However, in one randomized trial in which 440 patients were assigned to 12 days of triple therapy or reverse hybrid therapy (<a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> and <a href=\"topic.htm?path=pantoprazole-drug-information\" class=\"drug drug_general\">pantoprazole</a> for 12 days and <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> plus <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> for the initial seven days), eradication rates were significantly higher with reverse hybrid therapy (96 versus 89 percent) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/30\" class=\"abstract_t\">30</a>]. In contrast to patients who received clarithromycin triple therapy, clarithromycin resistance did not significantly impact eradication rates in patients treated with reverse hybrid therapy. </p><p class=\"headingAnchor\" id=\"H3158554386\"><span class=\"h4\">Sequential therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The 10-day clarithromycin-containing sequential therapy regimen consists of <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> and a PPI for five days, followed by <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> and <a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">tinidazole</a> (eg, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>) plus a PPI for five days (<a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/31\" class=\"abstract_t\">31</a>]. Given the complexity of the sequential therapy regimen and the lack of superiority to 14 day clarithromycin triple therapy in North America, clarithromycin-containing sequential therapy has not been uniformly endorsed by guidelines as a first-line therapy [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/8\" class=\"abstract_t\">8</a>]. (See <a href=\"#H2227870566\" class=\"local\">'Patients without risk factors for macrolide resistance'</a> above.)</p><p>In a 2013 meta-analysis of 46 randomized trials that included 13,532 patients who were assigned to sequential therapy or other regimens, the overall eradication rate for sequential therapy was 84 percent [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/32\" class=\"abstract_t\">32</a>]. Eradication rates with sequential therapy were significantly higher as compared with <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> triple therapy administered for 7 or 10 days. However, there was no significant difference in eradication rates between sequential therapy and 14 days of clarithromycin-based triple therapy or 10 to 14 days of bismuth quadruple therapy. The efficacy of sequential therapy varies widely by region [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/6\" class=\"abstract_t\">6</a>]. Randomized trials in Latin America and Asia have also demonstrated lower eradication rates with sequential therapy as compared with clarithromycin triple therapy; however, the efficacy of sequential therapy may be higher in Europe [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/33-37\" class=\"abstract_t\">33-37</a>]. </p><p class=\"headingAnchor\" id=\"H2609998802\"><span class=\"h3\">Levofloxacin based therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies evaluating the efficacy of <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> containing regimens in North America are lacking. Limited data suggest that fluoroquinolone resistance rates in North America are high. Levofloxacin resistance decreases the eradication success rate of levofloxacin containing regimens by 20 to 40 percent [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/6\" class=\"abstract_t\">6</a>]. However, based on results from international trials, levofloxacin triple therapy may have a role in the treatment of <em>H. pylori</em> as a salvage regimen [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"#H3817818346\" class=\"local\">'Approach to selecting an antibiotic regimen'</a> above and <a href=\"#H1181944356\" class=\"local\">'Salvage regimens'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">Levofloxacin</a><strong> triple therapy</strong> &mdash; Levofloxacin triple therapy consists of levofloxacin, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, and a PPI for 10 to 14 days. In a network meta-analysis eradication rates with levofloxacin triple therapy for 10 to 14 days were significantly higher than <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> triple therapy for seven days (90 versus 73 percent) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/29\" class=\"abstract_t\">29</a>]. Although not directly compared, the pooled eradication rate of levofloxacin triple therapy was also higher than clarithromycin triple therapy for 10 to 14 days (81 percent, 95% CI, 78 to 84 percent). <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">Metronidazole</a> can be substituted for amoxicillin in penicillin-allergic individuals.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">Levofloxacin</a><strong> quadruple therapy</strong> &mdash; Limited data support the use of quadruple therapy with levofloxacin, <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">omeprazole</a>, <a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">nitazoxanide</a>, and <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> (LOAD). In an open label prospective trial, <em>H. pylori</em> treatment-na&iuml;ve patients randomized to LOAD for 7 or 10 days had significantly higher eradication rates as compared with <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> triple therapy for 10 days (89, 90, and 73 percent, respectively) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/38\" class=\"abstract_t\">38</a>]. However, additional studies are needed to confirm these results and determine whether this more expensive regimen is cost-effective.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">Levofloxacin</a> <strong>sequential</strong> <strong>therapy</strong> &mdash; Levofloxacin sequential therapy consists of <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> and a PPI for five to seven days followed by levofloxacin, amoxicillin, a nitroimidazole and a PPI for five to seven days. A meta-analysis of six international trials compared the efficacy of fluoroquinolone sequential therapy for 10 to 14 days and either <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> triple therapy for 7 to 14 days or standard sequential therapy for 10 days [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/39\" class=\"abstract_t\">39</a>]. The pooled eradication rate with fluoroquinolone sequential therapy was significantly higher as compared with clarithromycin triple or standard sequential therapies combined (88 versus 71 percent). </p><p/><p class=\"headingAnchor\" id=\"H1650484992\"><span class=\"h1\">CONFIRMATION OF ERADICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tests to confirm eradication should be performed in all patients treated for <em>H. pylori</em>. Eradication may be confirmed by a urea breath test, fecal antigen test, or upper endoscopy performed four weeks or more after completion of antibiotic therapy. PPI therapy should be withheld for one to two weeks prior to testing [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/9\" class=\"abstract_t\">9</a>]. Endoscopy with biopsy for culture and sensitivity should be performed in patients with persistent <em>H. pylori</em> infection after two courses of antibiotic treatment. (See <a href=\"topic.htm?path=indications-and-diagnostic-tests-for-helicobacter-pylori-infection#H27\" class=\"medical medical_review\">&quot;Indications and diagnostic tests for Helicobacter pylori infection&quot;, section on 'Confirmation of eradication'</a>.)</p><p class=\"headingAnchor\" id=\"H3635965466\"><span class=\"h1\">TREATMENT FAILURE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 20 percent of patients fail an initial attempt at <em>H. pylori</em> eradication [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/40\" class=\"abstract_t\">40</a>]. Such patients require salvage therapy (<a href=\"image.htm?imageKey=GAST%2F112679\" class=\"graphic graphic_algorithm graphicRef112679 \">algorithm 2</a> and <a href=\"image.htm?imageKey=GAST%2F112172\" class=\"graphic graphic_table graphicRef112172 \">table 2</a>).</p><p class=\"headingAnchor\" id=\"H3167044966\"><span class=\"h2\">Factors associated with antibiotic treatment failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Factors associated with treatment failure include poor patient compliance and resistance of the patient&rsquo;s <em>H. pylori </em>strain to prescribed antibiotics. <em>H. pylori</em> is naturally resistant to several commonly used antibiotics, including <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>, <a href=\"topic.htm?path=trimethoprim-drug-information\" class=\"drug drug_general\">trimethoprim</a>, and sulfonamides [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/41\" class=\"abstract_t\">41</a>]. A specific mutation leading to <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> resistance appears to be associated with a reduced likelihood of eradication [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/42\" class=\"abstract_t\">42</a>]. Prior use of macrolide antibiotics, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, and <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> increases the risk of <em>H. pylori</em> resistance to these antibiotics [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/43\" class=\"abstract_t\">43</a>]. Clarithromycin resistance has a greater effect on treatment efficacy as compared with metronidazole resistance [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/24\" class=\"abstract_t\">24</a>]. The impact of metronidazole resistance can be overcome by increasing the dose, duration, or frequency of administration of metronidazole. Resistance rates to <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>, and <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> are low (&lt;5 percent).</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Salvage therapy for persistent H. pylori infection</span></p><p class=\"headingAnchor\" id=\"H2267030540\"><span class=\"h3\">Suggested approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with persistent <em>H. pylori </em>infection, the choice of antibiotic therapy should be guided by the patient&rsquo;s initial treatment regimen, the use of other antibiotics, and the presence of relevant antibiotic allergies. Antibiotics included in the initial regimen should generally be avoided [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/44\" class=\"abstract_t\">44</a>]. However, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> can be reused as resistance rarely develops. Patients with a reported history of penicillin allergy should be referred to an allergist to determine if they have a true penicillin allergy. A suggested approach to the selection of antibiotics for persistent <em>H. pylori</em> infection is outlined in the algorithm (<a href=\"image.htm?imageKey=GAST%2F112679\" class=\"graphic graphic_algorithm graphicRef112679 \">algorithm 2</a> and <a href=\"image.htm?imageKey=GAST%2F112172\" class=\"graphic graphic_table graphicRef112172 \">table 2</a>). (See <a href=\"topic.htm?path=an-approach-to-the-patient-with-drug-allergy\" class=\"medical medical_review\">&quot;An approach to the patient with drug allergy&quot;</a>.)</p><p>Culture with antibiotic sensitivity testing should be performed to guide antibiotic treatment in patients who have failed two prior treatment regimens. Compliance with medications should also be reinforced. We reserve the use of rifabutin-containing regimens for patients with &ge;3 previous antibiotic failures. </p><p>(See <a href=\"topic.htm?path=indications-and-diagnostic-tests-for-helicobacter-pylori-infection#H4099261000\" class=\"medical medical_review\">&quot;Indications and diagnostic tests for Helicobacter pylori infection&quot;, section on 'Bacterial culture and sensitivity testing'</a>.)</p><p class=\"headingAnchor\" id=\"H1181944356\"><span class=\"h3\">Salvage regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Salvage regimens in patients who have failed initial antibiotic therapy include (<a href=\"image.htm?imageKey=GAST%2F112172\" class=\"graphic graphic_table graphicRef112172 \">table 2</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bismuth quadruple therapy</strong> &mdash; Bismuth quadruple therapy should be used for 14 days when used as salvage regimen. In randomized trials performed in Europe, United States, and Asia eradication rates with 14-day salvage bismuth quadruple therapy were approximately 80 percent [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/9\" class=\"abstract_t\">9</a>]. Eradication rates were significantly higher in studies performed in Asia as compared with Europe and the United States (82 versus 74 percent) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/45-47\" class=\"abstract_t\">45-47</a>]. The overall eradication rate for 14-day bismuth quadruple therapy in these trials was higher in patients who had previously failed clarithromycin-based regimens without bismuth as compared with bismuth quadruple treatment (100 versus 53 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">Levofloxacin</a><strong> triple therapy</strong> &mdash; Levofloxacin-based triple therapy has demonstrated efficacy as a salvage regimen in patients who have failed initial <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> triple therapy or bismuth quadruple therapy. Levofloxacin triple therapy has also demonstrated efficacy in patients who have failed two prior attempts at treatment. In a pooled analysis from six European cohort studies, when used as a salvage regimen in patients who had failed two previous eradication attempts, levofloxacin triple therapy administered for 10 days has a pooled eradication rate of 73 percent [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/48\" class=\"abstract_t\">48</a>]. Most patients in these studies were treated with clarithromycin triple therapy followed by bismuth quadruple therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>High-dose dual therapy</strong> &mdash; High dose dual therapy with <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> and proton pump inhibitor (PPI) for 14 days is a salvage treatment option, particularly in patients in whom dual <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a><span class=\"nowrap\">/<a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a></span> resistance or <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> resistance is suspected. The pooled eradication rate of high-dose dual therapy with amoxicillin and PPI as a salvage regimen in three randomized trials performed in Europe and Asia was 78 percent [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/9\" class=\"abstract_t\">9</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">Clarithromycin</a><strong> based concomitant therapy</strong> &mdash; Of the clarithromycin-based regimens, only concomitant therapy (clarithromycin, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, a nitroimidazole, and a PPI) should be used as a salvage regimen. Clarithromycin-based therapy should be used only in patients with no risk factors for macrolide resistance (no prior macrolide exposure and local clarithromycin resistance known to be &lt;15 percent) [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/49,50\" class=\"abstract_t\">49,50</a>]. (See <a href=\"#H3453806024\" class=\"local\">'Clarithromycin-based therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a><strong> triple therapy</strong> &mdash; The rifabutin-based triple regimen consists of rifabutin, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, and a PPI twice daily for 10 days. In a meta-analysis of cohort studies that evaluated the efficacy of rifabutin triple therapy as salvage treatment, pooled eradication rates as a second, third, or <span class=\"nowrap\">fourth/fifth</span> line agent were 79, 66, and 70 percent respectively [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/51\" class=\"abstract_t\">51</a>]. Rifabutin-based triple therapy is expensive and can cause reversible myelotoxicity. It also has the potential to increase the prevalence of rifabutin-resistant mycobacteria.</p><p/><p class=\"headingAnchor\" id=\"H17104517\"><span class=\"h1\">ADJUVANT THERAPIES WITH UNCLEAR ROLE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of potential adjuvant therapies for <em>H. pylori</em> have been evaluated, but additional studies are needed to support their use.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Statins</strong> &mdash; Addition of statin therapy as an adjuvant to triple therapy has been associated with a reduction in <em>H. pylori</em> mediated inflammation and an increase in <em>H. pylori</em> eradication rates [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/52-54\" class=\"abstract_t\">52-54</a>]. However, large trials are needed to confirm these findings.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Probiotics </strong>&mdash; Probiotics may have an inhibitory effect on <em>H. pylori. </em>In addition, they may improve compliance with treatment by<em> </em>reducing antibiotic side effects. A meta-analysis that included 10 clinical trials of adjuvant probiotics in patients with <em>H. pylori </em>infection demonstrated higher cure rates and a reduction in the incidence of side effects in patients who received probiotic supplementation (pooled OR 2.1 and 0.3, respectively). However, studies included in this meta-analysis were at high risk of bias due to lack of blinding and inadequate allocation concealment. In addition, there was significant variability in the probiotics used and antibiotic treatment regimens to eradicate <em>H. pylori</em>. (See <a href=\"topic.htm?path=probiotics-for-gastrointestinal-diseases\" class=\"medical medical_review\">&quot;Probiotics for gastrointestinal diseases&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Vonoprazan</strong> &mdash; Limited data from retrospective studies suggest that the use of vonoprazan, an oral potassium-competitive acid blocker (PCAB), rather than a proton pump inhibitor, with <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> and <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> may increase <em>H. pylori</em> eradication rates [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/55,56\" class=\"abstract_t\">55,56</a>]. However, PCABs are not available outside of Asia, and data on safety and comparative efficacy with other antisecretory agents are limited [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/55\" class=\"abstract_t\">55</a>]. (See <a href=\"topic.htm?path=antiulcer-medications-mechanism-of-action-pharmacology-and-side-effects#H1072317995\" class=\"medical medical_review\">&quot;Antiulcer medications: Mechanism of action, pharmacology, and side effects&quot;, section on 'Potassium-competitive acid inhibitors'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3584616337\"><span class=\"h1\">TREATMENT DURING PREGNANCY AND LACTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When peptic ulcer disease is diagnosed in a woman who is pregnant, the mainstay of treatment is typically acid suppression [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/57\" class=\"abstract_t\">57</a>]. If <em>H. pylori</em> is present, treatment is typically deferred until after delivery. However, with the exception of bismuth, fluoroquinolones, and <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>, the other medications used for <em>H. pylori</em> eradication are low risk in pregnancy, especially after 14 weeks. This includes <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, and probably <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>. Moreover, there is some evidence that <em>H. pylori</em> can cause severe nausea and vomiting in pregnancy, including hyperemesis gravidarum [<a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/58,59\" class=\"abstract_t\">58,59</a>]. Thus, if indicated, <em>H. pylori</em> treatment should be considered in pregnancy. </p><p>Some of the medications typically used for the treatment of <em>H. pylori</em> are possibly unsafe for nursing infants (eg, bismuth, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a>). (See <a href=\"topic.htm?path=medical-management-of-gastroesophageal-reflux-disease-in-adults#H18\" class=\"medical medical_review\">&quot;Medical management of gastroesophageal reflux disease in adults&quot;, section on 'Pregnancy and lactation'</a> and <a href=\"topic.htm?path=prenatal-care-patient-education-health-promotion-and-safety-of-commonly-used-drugs#H1294336483\" class=\"medical medical_review\">&quot;Prenatal care: Patient education, health promotion, and safety of commonly used drugs&quot;, section on 'Antibiotics'</a>.)</p><p class=\"headingAnchor\" id=\"H2746670566\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-helicobacter-pylori\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Helicobacter pylori&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=h-pylori-infection-the-basics\" class=\"medical medical_basics\">&quot;Patient education: H. pylori infection (The Basics)&quot;</a> and <a href=\"topic.htm?path=gastritis-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Gastritis (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=helicobacter-pylori-infection-and-treatment-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Helicobacter pylori infection and treatment (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All patients with evidence of active infection with <em>H. pylori </em>should be offered treatment. The choice of initial antibiotic regimen to treat <em>H. pylori</em> should be guided by the presence of risk factors for macrolide resistance and the presence of a penicillin allergy. In patients with risk factors for macrolide resistance, clarithromycin-based therapy should be avoided (<a href=\"image.htm?imageKey=GAST%2F112678\" class=\"graphic graphic_algorithm graphicRef112678 \">algorithm 1</a> and <a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>). (See <a href=\"#H3817818346\" class=\"local\">'Approach to selecting an antibiotic regimen'</a> above.)</p><p/><p class=\"bulletIndent1\">Risk factors for macrolide resistance include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Prior exposure to macrolide therapy for any reason.</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>High local <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> resistance rates &ge;15 percent or eradication rates with clarithromycin-based triple therapy &le;85 percent.</p><p/><p class=\"bulletIndent1\">In the United States, given the limited information on antimicrobial resistance rates, we generally assume <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> resistance rates are greater than 15 percent unless local resistance data indicate otherwise. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For initial therapy in patients without risk factors for macrolide resistance, we suggest triple therapy with a proton pump inhibitor (PPI), <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> (1 g twice daily), and <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> (500 mg twice daily) for 14 days (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). We suggest substitution of amoxicillin with <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> only in penicillin-allergic individuals since metronidazole resistance is common and can reduce the efficacy of treatment (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H3453806024\" class=\"local\">'Clarithromycin-based therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest bismuth quadruple therapy as initial treatment in patients with risk factors for macrolide resistance (<a href=\"image.htm?imageKey=GAST%2F112678\" class=\"graphic graphic_algorithm graphicRef112678 \">algorithm 1</a> and <a href=\"image.htm?imageKey=GAST%2F112171\" class=\"graphic graphic_table graphicRef112171 \">table 1</a>). Quadruple therapy consists of a PPI <a href=\"topic.htm?path=bismuth-subsalicylate-drug-information\" class=\"drug drug_general\">bismuth subsalicylate</a>, two antibiotics (<a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> and <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>) or with a commercially available combination capsule containing bismuth subcitrate, metronidazole, and tetracycline four times daily for 14 days. (See <a href=\"#H6\" class=\"local\">'Salvage therapy for persistent H. pylori infection'</a> above and <a href=\"#H4045763521\" class=\"local\">'Bismuth quadruple therapy'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tests to confirm eradication should be performed in all patients treated for <em>H. pylori</em>. Eradication may be confirmed by a urea breath test, fecal antigen test, or upper endoscopy performed four weeks or more after completion of antibiotic therapy. PPI therapy should be withheld for one to two weeks prior to testing. (See <a href=\"#H1650484992\" class=\"local\">'Confirmation of eradication'</a> above and <a href=\"topic.htm?path=indications-and-diagnostic-tests-for-helicobacter-pylori-infection#H1886899784\" class=\"medical medical_review\">&quot;Indications and diagnostic tests for Helicobacter pylori infection&quot;, section on 'Diagnostic tests'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with persistent <em>H. pylori </em>infection, the choice of antibiotic therapy should be guided by the patient&rsquo;s initial treatment regimen and the presence of relevant antibiotic allergies (<a href=\"image.htm?imageKey=GAST%2F112679\" class=\"graphic graphic_algorithm graphicRef112679 \">algorithm 2</a> and <a href=\"image.htm?imageKey=GAST%2F112172\" class=\"graphic graphic_table graphicRef112172 \">table 2</a>). For patients failing a course of <em>H. pylori</em> treatment, we suggest an alternate regimen using a different combination of medications (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). In general, <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> and antibiotics used previously should be avoided if possible. (See <a href=\"#H6\" class=\"local\">'Salvage therapy for persistent H. pylori infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Culture with antibiotic sensitivity testing should be performed to guide antibiotic treatment in patients who have failed two prior treatment regimens. Compliance with medications should also be reinforced. We reserve the use of rifabutin-containing regimens for patients with &ge;3 prior antibiotic failures. (See <a href=\"#H6\" class=\"local\">'Salvage therapy for persistent H. pylori infection'</a> above.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/1\" class=\"nounderline abstract_t\">Qasim A, Sebastian S, Thornton O, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21:91.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/2\" class=\"nounderline abstract_t\">Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22:45.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/3\" class=\"nounderline abstract_t\">Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 2005; 10:157.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/4\" class=\"nounderline abstract_t\">Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/5\" class=\"nounderline abstract_t\">Graham DY, Hammoud F, El-Zimaity HM, et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 17:1229.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/6\" class=\"nounderline abstract_t\">Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112:212.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/7\" class=\"nounderline abstract_t\">Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10:1088.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/8\" class=\"nounderline abstract_t\">Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016; 151:51.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/9\" class=\"nounderline abstract_t\">Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/10\" class=\"nounderline abstract_t\">Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/11\" class=\"nounderline abstract_t\">Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/12\" class=\"nounderline abstract_t\">Graham DY, Shiotani A. Which Therapy for Helicobacter pylori Infection? Gastroenterology 2012; 143:10.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/13\" class=\"nounderline abstract_t\">Tepes B, O'Connor A, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2012. Helicobacter 2012; 17 Suppl 1:36.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/14\" class=\"nounderline abstract_t\">Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: sequential therapy for Helicobacter pylori eradication in children. Aliment Pharmacol Ther 2012; 36:534.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/15\" class=\"nounderline abstract_t\">Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34:1255.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/16\" class=\"nounderline abstract_t\">de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995; 30:401.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/17\" class=\"nounderline abstract_t\">Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105:65.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/18\" class=\"nounderline abstract_t\">McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362:1597.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/19\" class=\"nounderline abstract_t\">Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J 2012; 53:273.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/20\" class=\"nounderline abstract_t\">Akyildiz M, Akay S, Musoglu A, et al. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Eur J Intern Med 2009; 20:53.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/21\" class=\"nounderline abstract_t\">Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98:562.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/22\" class=\"nounderline abstract_t\">Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377:905.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/23\" class=\"nounderline abstract_t\">Venerito M, Krieger T, Ecker T, et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88:33.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/24\" class=\"nounderline abstract_t\">Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26:343.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/25\" class=\"nounderline abstract_t\">Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; :CD008337.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/26\" class=\"nounderline abstract_t\">Gisbert JP, Gonz&aacute;lez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14:1319.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/27\" class=\"nounderline abstract_t\">Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5:23.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/28\" class=\"nounderline abstract_t\">Wang B, Wang YH, Lv ZF, et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20:79.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/29\" class=\"nounderline abstract_t\">Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015; 351:h4052.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/30\" class=\"nounderline abstract_t\">Hsu PI, Kao SS, Wu DC, et al. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. Medicine (Baltimore) 2015; 94:e2104.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/31\" class=\"nounderline abstract_t\">Moayyedi P, Malfertheiner P. Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol 2009; 104:3081.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/32\" class=\"nounderline abstract_t\">Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347:f4587.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/33\" class=\"nounderline abstract_t\">Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104:3069.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/34\" class=\"nounderline abstract_t\">Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/35\" class=\"nounderline abstract_t\">Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381:205.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/36\" class=\"nounderline abstract_t\">Albrecht P, Kotowska M, Szajewska H. Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial. J Pediatr 2011; 159:45.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/37\" class=\"nounderline abstract_t\">Bontems P, Kalach N, Oderda G, et al. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011; 53:646.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/38\" class=\"nounderline abstract_t\">Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106:1970.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/39\" class=\"nounderline abstract_t\">Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis. Pharmacotherapy 2015; 35:719.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/40\" class=\"nounderline abstract_t\">Vakil N. Primary and secondary treatment for Helicobacter pylori in the United States. Rev Gastroenterol Disord 2005; 5:67.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/41\" class=\"nounderline abstract_t\">van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1:6.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/42\" class=\"nounderline abstract_t\">De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144:94.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/43\" class=\"nounderline abstract_t\">McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139:463.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/44\" class=\"nounderline abstract_t\">Malfertheiner P, Leodolter A, Peitz U. Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:119.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/45\" class=\"nounderline abstract_t\">Magaret N, Burm M, Faigel D, et al. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis 2001; 19:174.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/46\" class=\"nounderline abstract_t\">Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8:310.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/47\" class=\"nounderline abstract_t\">Cao Z, Chen Q, Zhang W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol 2015; 50:1185.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/48\" class=\"nounderline abstract_t\">Gisbert JP, H. pylori Study Group of the Spanish Gastroenterology Association. Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35:1484.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/49\" class=\"nounderline abstract_t\">Lamouliatte H, M&eacute;graud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003; 18:791.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/50\" class=\"nounderline abstract_t\">Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62:34.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/51\" class=\"nounderline abstract_t\">Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35:209.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/52\" class=\"nounderline abstract_t\">Nseir W, Diab H, Mahamid M, et al. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. Aliment Pharmacol Ther 2012; 36:231.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/53\" class=\"nounderline abstract_t\">Yamato M, Watanabe T, Higuchi K, et al. Anti-inflammatory effects of pravastatin on Helicobacter pylori-induced gastritis in mice. Dig Dis Sci 2007; 52:2833.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/54\" class=\"nounderline abstract_t\">Liao WC, Huang MZ, Wang ML, et al. Statin Decreases Helicobacter pylori Burden in Macrophages by Promoting Autophagy. Front Cell Infect Microbiol 2016; 6:203.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/55\" class=\"nounderline abstract_t\">Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65:1439.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/56\" class=\"nounderline abstract_t\">Sakurai K, Suda H, Ido Y, et al. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017; 23:668.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/57\" class=\"nounderline abstract_t\">Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131:283.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/58\" class=\"nounderline abstract_t\">Golberg D, Szilagyi A, Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet Gynecol 2007; 110:695.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori/abstract/59\" class=\"nounderline abstract_t\">Mansour GM, Nashaat EH. Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum. Arch Gynecol Obstet 2011; 284:843.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7 Version 36.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H4260690167\" id=\"outline-link-H4260690167\">INDICATIONS FOR TREATMENT</a></li><li><a href=\"#H545843828\" id=\"outline-link-H545843828\">INITIAL ANTIBIOTIC THERAPY</a><ul><li><a href=\"#H3817818346\" id=\"outline-link-H3817818346\">Approach to selecting an antibiotic regimen</a><ul><li><a href=\"#H1285242199\" id=\"outline-link-H1285242199\">- Patients with risk factors for macrolide resistance</a></li><li><a href=\"#H2227870566\" id=\"outline-link-H2227870566\">- Patients without risk factors for macrolide resistance</a></li></ul></li><li><a href=\"#H740837509\" id=\"outline-link-H740837509\">Duration of therapy</a></li><li><a href=\"#H1588496158\" id=\"outline-link-H1588496158\">Tolerability and compliance</a></li><li><a href=\"#H1032686964\" id=\"outline-link-H1032686964\">Antibiotic regimens</a><ul><li><a href=\"#H4045763521\" id=\"outline-link-H4045763521\">- Bismuth quadruple therapy</a></li><li><a href=\"#H3453806024\" id=\"outline-link-H3453806024\">- Clarithromycin-based therapy</a><ul><li><a href=\"#H3153939224\" id=\"outline-link-H3153939224\">Triple therapy</a></li><li><a href=\"#H3788833783\" id=\"outline-link-H3788833783\">Concomitant therapy</a></li><li><a href=\"#H1644077299\" id=\"outline-link-H1644077299\">Hybrid therapy</a></li><li><a href=\"#H3158554386\" id=\"outline-link-H3158554386\">Sequential therapy</a></li></ul></li><li><a href=\"#H2609998802\" id=\"outline-link-H2609998802\">- Levofloxacin based therapy</a></li></ul></li></ul></li><li><a href=\"#H1650484992\" id=\"outline-link-H1650484992\">CONFIRMATION OF ERADICATION</a></li><li><a href=\"#H3635965466\" id=\"outline-link-H3635965466\">TREATMENT FAILURE</a><ul><li><a href=\"#H3167044966\" id=\"outline-link-H3167044966\">Factors associated with antibiotic treatment failure</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Salvage therapy for persistent H. pylori infection</a><ul><li><a href=\"#H2267030540\" id=\"outline-link-H2267030540\">- Suggested approach</a></li><li><a href=\"#H1181944356\" id=\"outline-link-H1181944356\">- Salvage regimens</a></li></ul></li></ul></li><li><a href=\"#H17104517\" id=\"outline-link-H17104517\">ADJUVANT THERAPIES WITH UNCLEAR ROLE</a></li><li><a href=\"#H3584616337\" id=\"outline-link-H3584616337\">TREATMENT DURING PREGNANCY AND LACTATION</a></li><li><a href=\"#H2746670566\" id=\"outline-link-H2746670566\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H8690641\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/7|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=GAST/112678\" class=\"graphic graphic_algorithm\">- H. pylori treatment</a></li><li><a href=\"image.htm?imageKey=GAST/112679\" class=\"graphic graphic_algorithm\">- H. pylori salvage</a></li></ul></li><li><div id=\"GAST/7|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/112171\" class=\"graphic graphic_table\">- Recommended first-line therapies for H pylori infection</a></li><li><a href=\"image.htm?imageKey=GAST/112172\" class=\"graphic graphic_table\">- Salvage therapies for H pylori infection</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=an-approach-to-the-patient-with-drug-allergy\" class=\"medical medical_review\">An approach to the patient with drug allergy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiulcer-medications-mechanism-of-action-pharmacology-and-side-effects\" class=\"medical medical_review\">Antiulcer medications: Mechanism of action, pharmacology, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=azithromycin-clarithromycin-and-telithromycin\" class=\"medical medical_review\">Azithromycin, clarithromycin, and telithromycin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacteriology-and-epidemiology-of-helicobacter-pylori-infection\" class=\"medical medical_review\">Bacteriology and epidemiology of Helicobacter pylori infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fluoroquinolones\" class=\"medical medical_review\">Fluoroquinolones</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=indications-and-diagnostic-tests-for-helicobacter-pylori-infection\" class=\"medical medical_review\">Indications and diagnostic tests for Helicobacter pylori infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-management-of-gastroesophageal-reflux-disease-in-adults\" class=\"medical medical_review\">Medical management of gastroesophageal reflux disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metronidazole-an-overview\" class=\"medical medical_review\">Metronidazole: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gastritis-the-basics\" class=\"medical medical_basics\">Patient education: Gastritis (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=h-pylori-infection-the-basics\" class=\"medical medical_basics\">Patient education: H. pylori infection (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=helicobacter-pylori-infection-and-treatment-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Helicobacter pylori infection and treatment (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prenatal-care-patient-education-health-promotion-and-safety-of-commonly-used-drugs\" class=\"medical medical_review\">Prenatal care: Patient education, health promotion, and safety of commonly used drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=probiotics-for-gastrointestinal-diseases\" class=\"medical medical_review\">Probiotics for gastrointestinal diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=proton-pump-inhibitors-overview-of-use-and-adverse-effects-in-the-treatment-of-acid-related-disorders\" class=\"medical medical_review\">Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-helicobacter-pylori\" class=\"medical medical_society_guidelines\">Society guideline links: Helicobacter pylori</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tetracyclines\" class=\"medical medical_review\">Tetracyclines</a></li></ul></div></div>","javascript":null}